Astria Therapeutics to Present at Upcoming C1 Inhibitor Deficiency and Angioedema Workshop
BOSTON--(BUSINESS WIRE)-- Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present at the 14 th C1 Inhibitor Deficiency and Angioedema Workshop in Budapest, Hungary on May 31, 2025.
Dr. Marc A. Riedl, Professor of Medicine and Clinical Director of the U.S. HAEA Angioedema Center at the University of California, San Diego, will present safety and efficacy data from the Phase 1a and Phase 1b/2 trials of navenibart in a presentation titled, 'Navenibart for Hereditary Angioedema (HAE): Analysis of Safety, Pharmacokinetic, and Pharmacodynamic Data From Phase 1a and Phase 1b/2 ALPHA-STAR Trial.' The presentation will take place at 2:45pm CET on Saturday, May 31 at the Ensana Thermal Hotel Margitsziget in Budapest.
About Astria Therapeutics:
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by allergic and immunologic diseases. Our lead program, navenibart (STAR-0215), is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Our second program, STAR-0310, is an investigational monoclonal antibody OX40 antagonist in clinical development for the treatment of atopic dermatitis. Learn more about our company on our website, www.astriatx.com, or follow us on Instagram @AstriaTx and on Facebook and LinkedIn.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
15 minutes ago
- Business Wire
Milliman analysis: Public pension funding stable in April after plans end volatile month with slight market gain
SEATTLE--(BUSINESS WIRE)-- Milliman, Inc., a premier global consulting and actuarial firm, today released the latest results of its Public Pension Funding Index (PPFI), which analyzes data from the nation's 100 largest public defined benefit plans. Despite April market swings caused by trade and tariff uncertainty, the Milliman 100 PPFI plans closed the month with estimated investment gains of 0.4% in aggregate. Individual plans' estimated returns ranged from -1.8% to 1.4%. Combined, the plans added about $24 billion in market value during the period, rising to $5.213 trillion as of April 30. Meanwhile, the deficit between plan assets and liabilities was unchanged since March at $1.340 trillion. The PPFI funded ratio rose from 79.5% as of March 31 to 79.6% as of April 30. 'After significant market fluctuations caused by trade policy announcements, it was somewhat surprising to see the public pension funded status inch upward during April,' said Becky Sielman, co-author of the Milliman PPFI. 'By the end of the month, 25 plans were still more than 90% funded and 12 plans were less than 60% funded, the same breakdown observed in March—demonstrating that public pensions are well-positioned to withstand turbulent markets.' Public Pension Funding Index or Milliman's full range of annual Pension Funding Studies. To receive regular updates of Milliman's pension funding analysis, contact us at pensionfunding@ About Milliman Milliman leverages deep expertise, actuarial rigor, and advanced technology to develop solutions for a world at risk. We help clients in the public and private sectors navigate urgent, complex challenges—from extreme weather and market volatility to financial insecurity and rising health costs—so they can meet their business, financial, and social objectives. Our solutions encompass insurance, financial services, healthcare, life sciences, and employee benefits. Founded in 1947, Milliman is an independent firm with offices in major cities around the globe. Visit us at
Yahoo
15 minutes ago
- Yahoo
Roanoke man living with ALS is on a mission to help others
ROANOKE, VA (WFXR) — A Roanoke man living with ALS, also known as Lou Gehrig's Disease, is working to spread awareness and understanding about the disease, and make it livable for everyone until a cure can be found. 'I don't think you can ever be ready for a medical change that totally alters your trajectory in life,' said Mark Kary, who is living with ALS. ALS is a neurotmesuclar disease where the brain stops communicating with the muscles. For some, a person might lose the ability to walk, talk, eat, breathe, and it can sometimes be fatal. 'If I want to go into my emails, I can scroll down with my nose,' shared Kary. Mark Kary is 75 years old and is living with ALS. He said that right around the time of his retirement, he started to notice some weakness in his left arm. 'My brother, who was a doctor, found it, and that was about 12 years ago, which is a real anomaly time-wise. And I wasn't diagnosed until about five years ago,' said Kary. Mark's version of ALS is extremely rare. 'Only affected thus far my arms, hands, and shoulders, which have atrophied or, as I like to say, my arms are for decoration only,' shared Kary. Even with the diagnosis, the disease hasn't taken away his appetite for life. Every day the sun comes up is a beautiful day. One of the things I say is, how I get things done is with the hands of others.' Mark Kary His arms, hands, and shoulders might not work as well as they used to, but that doesn't stop him; he said he just had to adapt. 'Think about personal hygiene, anything you can do with your hands. I can't do,' shared Kary. 'I can still brush my teeth with an electric toothbrush, but that does take, you know, a four-step process.' I think you have to have a mission in life, no matter how brief.' Mark Kary 'For most people who have ALS, they don't have the timeframe that I have been blessed with,' shared Kary. And with the time Mark does have, he has created the ALS Red Ball Express. It's a visual and digital aid that you may have spotted on the back of cars. 'I want people to walk over and point their phone at it and get a connection to information,' said Kary. Whether it's connecting people with information or raising funds for the ALS Association, Mark is on a mission to ensure there is a visual representation of ALS on the roads in Roanoke every day of the year. Mark's story doesn't end, He's also been busy advocting for disabled people with adaptive access in Roanoke. A few years ago, he spoke with the City Manager, and helped put in place the Star City's first 'open access barrier-free parking' in downtown. Those are parking spaces specially set aside for disabled drivers, so they can park in timed spaces, for up to 10 hours. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
19 minutes ago
- Yahoo
Nvidia stock falls as Trump says China 'violated' trade deal with US
Nvidia (NVDA) stock dropped as much as 2% Friday morning after US President Trump claimed that China had 'totally violated' an agreement with the US. The tech-heavy Nasdaq (^IXIC) fell 0.3%, while the S&P 500 (^GSPC) was down just 0.1% late Friday morning. "The bad news is that China, perhaps not surprisingly to some, HAS TOTALLY VIOLATED ITS AGREEMENT WITH US," Trump said in a post on Truth Social. "So much for being Mr. NICE GUY!" The US and China agreed to temporarily reduce sky-high tariff rates in mid-May after a meeting between US Treasury Secretary Scott Bessent and Chinese Vice Premier He Lifeng in Switzerland. In what the White House called a 'historic deal,' the US dropped its duties on China to 30%, while China decreased its tariff on the US to 10% and agreed to 'suspend or remove the non-tariff countermeasures.' But late Thursday, Bessent said in an interview with Fox News that US-China trade talks were 'a bit stalled.' Trump did not give further details about how China had violated its preliminary agreement with the US, but US Trade Representative Jamieson Greer echoed the president's sentiments in an interview with CNBC Friday, saying that 'the Chinese are slow rolling their compliance.' While Nvidia was largely unscathed by the import tax on Chinese goods enacted in April — since most of its chips are made in Taiwan and then manufactured in servers in that country or Mexico — the company took a $5.5 billion hit from the Trump administration's separate, recent ban on sales of its chips to China. Nvidia makes specialized, lower performance versions of its Hopper AI chips for the China market called H20. Nvidia revealed in its latest quarterly earnings report this week that it lost $2.5 billion in sales in the first quarter due to the ban and expects another $8 billion loss in the second quarter. 'China is, and will remain the largest overhang on NVDA shares until we get resolution from the Trump administration,' DA Davidson analyst Gil Luria said in a note to investors Thursday. China is one of Nvidia's biggest markets. Nvidia CEO Jensen Huang said the company has no new products planned for the Chinese market. 'We don't have anything at the moment, but we're considering it,' he told analysts following the company's earnings release Wednesday. 'Obviously, the limits are quite stringent at the when the time comes, we'll engage the [Trump] administration and discuss that.' Some on Wall Street remain optimistic about Nvidia's China prospects. 'We remain convinced that there will be at least some recovery of the China opportunity,' wrote Morgan Stanley analyst Joseph Moore in a note to investors Thursday. Even with Friday's drop, Nvidia stock was on track to notch a more than 3% gain for the trading week. Nvidia shares rose 3% Thursday after the AI chipmaker reported first quarter revenue that surpassed Wall Street's expectations despite the China-related headwinds. Laura Bratton is a reporter for Yahoo Finance. Follow her on Bluesky @ Email her at Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
